Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Plexxikon, Inc.
The company is selling 6,556,000 shares at $25 a share to support the commercialization of its AquaBeam robotic system for minimally invasive treatment of benign prostatic hyperplasia.
The Daiichi Sankyo affiliate successfully argued that Novartis willfully infringed two patents covering its discoveries in the BRAF inhibitor drug class, getting nearly $178m in damages and future royalties.
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
Plus deals involving Zai Lab/MacroGenics, Ono/Rafael Pharmaceuticals, Beijing Podconley/Norgine, Nuance/Verona and BeiGene/Shoreline.